Literature DB >> 20376039

Taking thalidomide out of rehab.

Rosemary J Akhurst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20376039      PMCID： PMC2917634          DOI： 10.1038/nm0410-370

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

1.  Genetic heterogeneity of angiogenesis in mice.

Authors:  R M Rohan; A Fernandez; T Udagawa; J Yuan; R J D'Amato
Journal:  FASEB J       Date:  2000-05       Impact factor: 5.191

2.  Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.

Authors:  Dimitri Flieger; Sabine Hainke; Wolfgang Fischbach
Journal:  Ann Hematol       Date:  2006-06-29       Impact factor: 3.673

3.  Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia.

Authors:  A Bourdeau; M E Faughnan; M L McDonald; A D Paterson; I R Wanless; M Letarte
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  Agents that increase cAMP accumulation block endothelial c-sis induction by thrombin and transforming growth factor-beta.

Authors:  T O Daniel; V C Gibbs; D F Milfay; L T Williams
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

5.  Gap junction communication mediates transforming growth factor-beta activation and endothelial-induced mural cell differentiation.

Authors:  Karen K Hirschi; Janis M Burt; Kendal D Hirschi; Cuiping Dai
Journal:  Circ Res       Date:  2003-08-14       Impact factor: 17.367

Review 6.  Thalidomide-induced limb defects: resolving a 50-year-old puzzle.

Authors:  Neil Vargesson
Journal:  Bioessays       Date:  2009-12       Impact factor: 4.345

7.  Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.

Authors:  Andrew Mitchell; Leon A Adams; Gerry MacQuillan; Jon Tibballs; Rohan vanden Driesen; Luc Delriviere
Journal:  Liver Transpl       Date:  2008-02       Impact factor: 5.799

8.  Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.

Authors:  Xiping Li; Xuyi Liu; Jie Wang; Zengli Wang; Wei Jiang; Eddie Reed; Yi Zhang; Yuanlin Liu; Q Quentin Li
Journal:  Anticancer Res       Date:  2003 May-Jun       Impact factor: 2.480

9.  Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice.

Authors:  Yang Tang; Margaret L McKinnon; Li Ming Leong; Sarah A B Rusholme; Susana Wang; Rosemary J Akhurst
Journal:  Hum Mol Genet       Date:  2003-07-01       Impact factor: 6.150

10.  Genetic loci that control vascular endothelial growth factor-induced angiogenesis.

Authors:  Michael S Rogers; Richard M Rohan; Amy E Birsner; Robert J D'Amato
Journal:  FASEB J       Date:  2003-09-04       Impact factor: 5.191
View more
  4 in total

Review 1.  Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.

Authors:  Roberta Olmo Pinheiro; Jorgenilce de Souza Salles; Euzenir Nunes Sarno; Elizabeth Pereira Sampaio
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 2.  Functional Validation of Osteoporosis Genetic Findings Using Small Fish Models.

Authors:  Erika Kague; David Karasik
Journal:  Genes (Basel)       Date:  2022-01-30       Impact factor: 4.096

3.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

4.  Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.

Authors:  Naoko Arichi; Yozo Mitsui; Miho Hiraki; Sigenobu Nakamura; Takeo Hiraoka; Masahiro Sumura; Hiroshi Hirata; Yuichiro Tanaka; Rajvir Dahiya; Hiroaki Yasumoto; Hiroaki Shiina
Journal:  Oncoscience       Date:  2015-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.